# Steve Hall

> Steve Hall is a Series A investor at Lilly Ventures backing Biotechnology and Health Care. See 17 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Lilly Ventures](https://shizune.co/investors/profile/lilly-ventures)
- Location: Indianapolis, United States
- Total investments: 17
- Last investment: Dec 2020
- Lead investor: 24%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/steve-hall/10/313/122

Steve Hall is a Board Member at Kymera Therapeutics. He brings more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations to Lilly Ventures.Prior to joining Lilly Ventures, Steve was Senior Vice President, Research and Development, at Serenex, Inc. where he was also a co-founder.There he recruited and led a team in developing a novel discovery technology and applied it to a project that advanced from a novel screen to first patient dosed in just over three years. This novel orally-active Hsp90 inhibitor was the subject of strong interest across the industry and led to the acquisition of Serenex by Pfizer in April 2008.Prior to joining Serenex, Steve was Site Director, Sphinx Labs, Eli Lilly where he oversaw lead generation efforts in the areas of combinatorial chemistry, automation, high-throughput screening, biomolecular research, and information technology. There he was a key member of a small team that developed and executed a strategy to partner Lilly’s expertise in high-throughput chemistry with three Japanese pharmaceutical companies with an aggregate value of more than $75MM. Steve is the author of more than 40 papers and 60 patents. He received his BS in chemistry from Central Michigan University and his Ph.D. in organic chemistry from Massachusetts Institute of Technology.Steve currently sits on the boards of FORMA Therapeutics, Hydra Biosciences, InnoCentive, and Cerulean Pharma. He also is a board observer at Avid Radiopharmaceuticals and Viamet.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 41% |
| Health Care | 4 | 24% |
| Pharmaceutical | 4 | 24% |
| Therapeutics | 3 | 18% |
| Diabetes | 1 | 6% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 24% |
| Series C | 4 | 24% |
| Series D | 3 | 18% |
| Seed | 2 | 12% |
| Series B | 2 | 12% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pienza | Pienza is ideate, fund, and build SaaS unicorns with high conviction and high time & capital concentration. | $5.1M | Seed | Dec 08, 2020 |  |
| Nimbus Therapeutics | Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders. | $65M | Series C | Jun 05, 2018 |  |
| Nimbus Therapeutics | Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders. | $43M | Series B | Mar 19, 2015 |  |
| Lysosomal Therapeutics | Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish aunique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. |  | Series A | Feb 03, 2015 |  |
| Viamet Pharmaceuticals | Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allowsthem to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors. | $60M | Series D | Oct 21, 2014 |  |
| Numerate | Numerate is a group of cutting-edge scientists and engineers trying to solve very difficult problems at the interface of data science, machine learning, cloud scale analytics and medicinal chemistry. We have developed a computational platform that can predict how a potential drug will behave in the lab and the body. We use this platform toprocess large spaces of chemistry while searching for therapies for some of the world’s most important diseases, such as, obesity, heart failure, Alzheimer’s, and Huntington’s disease. Our platform makes the drug development process cheaper, faster, and results in higher success rates than traditional approaches. |  | Series C | Jun 06, 2014 |  |
| Lysosomal Therapeutics | Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish aunique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. | $4.8M | Seed | May 12, 2014 |  |
| Cerulean Pharma | Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively havea significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center. | $13M | Private Equity | Dec 14, 2012 |  |
| Cerulean Pharma | Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively havea significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center. |  | Series D | Dec 15, 2011 |  |
| Nimbus Therapeutics | Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders. | $24M | Series A | Jun 28, 2011 |  |

10 of 17 investments shown.

## Co-investors
- [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 5 deals together
- [BioAdvance](https://shizune.co/investors/profile/bioadvance) — VC Fund, 3 deals together
- [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners) — VC Fund, 3 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 3 deals together
- [RK Ventures Group](https://shizune.co/investors/profile/rk-ventures-group) — VC Fund, 3 deals together
- [AllianceBernstein](https://shizune.co/investors/profile/alliancebernstein) — VC Fund, 2 deals together

## About Lilly Ventures

VC Fund · Indianapolis, United States

Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. Its primary goal is to facilitate the success of companies in its areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under managementand focuses on three major areas of interest. It partner actively with the management teams of its portfolio companies to realize the potential of their technologies.

2 contacts available at Lilly Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Lisa Belas | Office Manager | https://shizune.co/investors/profile/lisa-belas |
| Steve Hall | Venture Partner | https://shizune.co/investors/profile/steve-hall-3 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Steve Hall invest in?

Steve Hall invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series C stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Steve Hall last invest?

The most recent investment recorded for Steve Hall closed in Dec 2020. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co